Neurology. 1993 May;43(5):876-9.

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.

Source

Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 28092.

Abstract

We report the treatment of four patients with inclusion-body myositis (IBM) and severe slowly progressive weakness using high-dose intravenous immunoglobulin (IVIg). After two monthly infusions, the strength of the proximal and less atrophic muscle groups improved or normalized in three of the four patients. The improvement lasted from 2 to 4 months. Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy. In view of the high cost of IVIg, the unexpected but encouraging results from this pilot study warrant a controlled trial.

PMID:: 8492940; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Case Reports

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Ovid Technologies, Inc.

Medical

Myositis - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. [J Neurol. 2000]
High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.
Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D. J Neurol. 2000 Jan; 247(1):22-8.
Inclusion body myositis: treatment with intravenous immunoglobulin. [Neurology. 1994]
Inclusion body myositis: treatment with intravenous immunoglobulin.
Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Neurology. 1994 Aug; 44(8):1516-8.
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. [Neurology. 2001]
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. Neurology. 2001 Feb 13; 56(3):323-7.
Review Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. [Neurology. 1998]
Review Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
Dalakas MC. Neurology. 1998 Dec; 51(6 Suppl 5):S37-45.
Review IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. [J Neurol. 2005]
Review IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I. J Neurol. 2005 May; 252 Suppl 1:I14-8.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Intravenous immunoglobulin in neurological disease: a specialist review. [J Neurol Neurosurg Psychiatry....]
Review Intravenous immunoglobulin in neurological disease: a specialist review.
Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, et al. J Neurol Neurosurg Psychiatry. 2002 Apr; 72(4):440-8.
Review Intravenous immunoglobulin treatment in neurological diseases. [J Neurol Neurosurg Psychiatry....]
Review Intravenous immunoglobulin treatment in neurological diseases.
Otten A, Vermeulen M, Bossuyt PM, Otten A. J Neurol Neurosurg Psychiatry. 1996 Apr; 60(4):359-61.
Clinical evaluation of plasma exchange and high dose intravenous immunoglobulin in a patient with Isaacs' syndrome. [J Neurol Neurosurg Psychiatry....]
Clinical evaluation of plasma exchange and high dose intravenous immunoglobulin in a patient with Isaacs' syndrome.
Ishii A, Hayashi A, Ohkoshi N, Oguni E, Maeda M, Ueda Y, Ishii K, Arasaki K, Mizusawa H, Shoji S. J Neurol Neurosurg Psychiatry. 1994 Jul; 57(7):840-2.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.
Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.
Neurology. 1993 May ;43(5):876-9.

PubMed
Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancem...
Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
J Gen Virol. 1993 May ;74 ( Pt 5):839-44.

PubMed
Barriers to human immunodeficiency virus related risk reduction among male stree...
Barriers to human immunodeficiency virus related risk reduction among male street prostitutes.
Health Educ Q. 1993 Summer ;20(2):261-73.

PubMed
A second look at delayed splenic rupture.
A second look at delayed splenic rupture.
Arch Surg. 1977 Apr ;112(4):422-5.

PubMed
Magnetic resonance imaging and the evaluation of tarsal tunnel syndrome.
Magnetic resonance imaging and the evaluation of tarsal tunnel syndrome.
Foot Ankle. 1993 Mar-Apr ;14(3):159-64.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: